New Results for Vutrisiran and Patisiran Presented at 2023 AAN Annual Meeting

24 Apr, 2023 New Results for Vutrisiran and Patisiran Presented at 2023 AAN Annual Meeting

New data from a post-hoc analysis of the HELIOS-A Phase 3 study comparing efficacy outcomes with vutrisiran versus patisiran in hATTR amyloidosis with polyneuropathy were presented during the 2023 AAN Annual Meeting. Final results from a Phase 4 observational study evaluating the effect of patisiran on polyneuropathy and cardiomyopathy in patients with hATTR amyloidosis with V122I/T60A variants were also presented.

Polydefkis, et al. “Comparison of Efficacy Outcomes with Vutrisiran vs. Patisiran in hATTR Amyloidosis with Polyneuropathy: Post-hoc Analysis of the HELIOS-A Study”

Comenzo, et al. “Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with hATTR Amyloidosis with V122I/T60A Variants: A Phase 4 Observational Study”